Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced or metastatic urothelial cancer
NL-OMON49675Phase 2Completed
- Sponsor
- PPD
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bempegaldesleukin and nivolumab in transitional cell carcinoma (TCC), sponsored by PPD. Primary endpoint: Objective response rate in PD-L1 low tumors. Started Oct 2019; status: completed.
02
Drugs
bempegaldesleukinnivolumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON49675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49675.